Evidence map›Paper›PMID 36263064›Full record

ArticlebioRxiv : the preprint server for biology2022

Evaluation of endogenous and therapeutic 25-hydroxycholesterols in murine models of pulmonary SARS-CoV-2 infection.

Michael B Fessler, Jennifer Madenspacher, Paul J Baker, Kerry L Hilligan, Ehydel Castro, Julie Meacham, Shih-Heng Chen, Reed F Johnson, Negin P Martin, C J Tucker and 3 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Michael B FesslerImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Jennifer MadenspacherImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Paul J BakerInflammation & Innate Immunity Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Kerry L HilliganImmunobiology Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Ehydel CastroInflammation & Innate Immunity Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Julie MeachamImmunity, Inflammation and Disease Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Shih-Heng ChenViral Vector Core Facility, Neurobiology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Reed F JohnsonSARS-CoV-2 Virology Core, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Negin P MartinViral Vector Core Facility, Neurobiology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
C J TuckerFluorescence Microscopy and Imaging Center, Signal Transduction Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Debabrata MahapatraIntegrated Laboratory Systems, LLC, Research Triangle Park, NC 27709.
Mark CestaDivision of the National Toxicology Program, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709.
Katrin D Mayer-BarberInflammation & Innate Immunity Unit, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
National Institutes of Health · USTriangle · US

Funding

Cell Signaling of Host DefenseZ01ES102005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI FESSLER, MICHAEL B · 2006 to 2008
$3.3M
Mechanisms of sexual Zika virus transmission and early immunopathogenesisR21AI129303 · NIAID · UNIVERSITY OF WASHINGTON · PI VOJTECH, LUCIA N · 2017 to 2018
$426k
Intramural NIH HHS Z01 ES102005NIAID NIH HHS R21 AI129303
6 · The paper itself

Abstract

Oxysterols (i.e., oxidized cholesterol species) have complex roles in biology. 25-hydroxycholesterol (25HC), a product of activity of cholesterol-25-hydroxylase (CH25H) upon cholesterol, has recently been shown to be broadly antiviral, suggesting therapeutic potential against SARS-CoV-2. However, 25HC can also amplify inflammation and tissue injury and be converted by CYP7B1 to 7α,25HC, a lipid with chemoattractant activity via the G protein-coupled receptor, EBI2/GPR183. Here, using

Indexed as

25-hydroxycholesterolacute lung injurycholesterol-25-hydroxylaseEBI2Gpr183oxysterolpneumoniaSARS-CoV-2

Identifiers

PMID36263064
PMCPMC9580384
OpenAlexW4295812488

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.